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Abstract 
 
Electronic pacemakers are widely used to treat cardiac pacing problems, but the devices have 
many inherent limitations. Pacemaking cells, which are hyperpolarization-activated cyclic nucleotide 
gated (HCN) transfected human mesenchymal stem cells (hMSCs), show promise as a solution to these 
problems, but these cells must be contained at the implant site to protect the patient and preserve 
functionality. This project aims to design and fabricate a device that is capable of preventing cell 
migration while allowing for cell-cell interactions and enabling minimally invasive delivery. A 
polyurethane/polyethylene terephthalate blended, micropatterned scaffold was created to achieve superior 
mechanical strength while maintaining low thickness necessary gap junction formation between cells. A 
method for heat sealing, which utilizes a 150o F heating element, was devised and shown effective for 
completely sealing all edges of a folded flat scaffold. Migration and implant testing of the final design 
suggests that cells could be properly contained at the implant site without risking damage to the device 
caused by forces during implantation.  
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Chapter 1 Introduction 
 
Implantation of permanent electronic cardiac pacemakers is a common medical procedure in the 
United States that effectively treats cardiac pacing problems and total failure of the heart’s natural 
pacemaker. According to the American Heart Association, approximately 358,000 pacemaker procedures 
are performed annually (Roger 2010). Current pacemakers consist of a battery pack and controller, which 
are implanted near the right clavicle, and metallic leads, which carry electronic impulses through blood 
vessels from the battery pack to the patient’s heart. 
Though these devices cure pacing problems, their design may result in several insufficiencies that 
require revision surgeries to repair. Because the leads are subjected to millions of loading cycles as blood 
pulses around them, there is a significant risk of lead failure.  Additionally, the battery pack has a finite 
lifespan and must eventually be replaced, and the devices are sensitive to magnetic fields so patients are 
restricted from MRIs and CT scans. Furthermore, re-operation is needed in pediatric patients to adjust the 
device to changes in body size. Finally, most permanent pacemakers are incapable of responding at all to 
physical and emotional stress, greatly limiting the patient’s activities (Rosen et al. 2004).   
 Biological pacemakers are cell based pacing devices that utilize genetically modified stem cells to 
generate electrical pacing signals. They have the potential to help millions of people by alleviating 
problems and limitations created by current permanent electronic pacemakers. Previous studies have 
already demonstrated their effectiveness at pacemaking canine and murine models in vitro (Rosen et. al, 
2004). Biological pacemakers would eliminate the chance of lead failure, the burden of finite battery life, 
limited responsiveness to physical and emotional stress of the patient, re-operations in pediatric patients, 
and sensitivity to magnetic fields. However, safety concerns around current biological pacemakers, which 
use hyperpolarization-activated cyclic nucleotide gated channel (HCN) transfected human mesenchymal 
stem cells (hMSCs), have limited their translation to the clinic. Transfected cells may become malignant, 
resulting in tumor formation. In addition, these cells may wander away from the site of delivery resulting 
in a current density too low to continue pacing the heart. To make biological pacemakers a viable 
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treatment method for cardiac arrhythmias and natural pacemaker failure, a device that is implantable, 
prevents cell migration, and does not inhibit cell-cell interactions must be developed.   
 Previous studies found that an electrospun polyurethane matrix sheath with pores smaller than 3.0 
µm was effective at containing hMSCs, but noted that the sheath must be thin enough to allow cells to 
form gap junctions through these pores. Though earlier designs effectively restrained the cells and 
appeared to enable gap junction formation across the membrane, the designs were not deliverable to the 
heart or capable of sufficient cell seeding and thus were not fully functional. The team aims to address 
this problem by designing a deliverable and implantable device while optimizing cell retention, gap 
junction formation across the membrane, and cell attachment and viability.  
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Chapter 2 Literature Review 
 
Cardiovascular Disease (CVD), affecting approximately 82.6 million Americans, is the leading 
cause of death among both men and women in the United States. CVD also accounts for very high 
morbidity rates and cost in terms of disease treatment. The most common types of CVD include Coronary 
Heart Disease (CHD), hypertension, stroke, congestive heart failure and arrhythmias (Institute of 
Medicine, 2011).  
2.1 Anatomy of the Heart 
 
The heart is a hollow muscular organ that lies along the midline of two bony structures: posterior 
to the sternum and anterior to the vertebrae. The human heart is comparable to the size of a clenched fist, 
and has a tapered bottom or apex, which is located slightly to the left of the sternum. The heart is enclosed 
in a double-walled membrane called the pericardial sac. The outer layer of this membrane is a tough 
fibrous covering that helps anchor the heart and maintain its position in the chest during the cardiac cycle. 
The inner lining of the sac secretes a thin pericardial fluid that prevents friction between the pericardial 
layers during the beating of the heart (Sherwood, 2008). 
The heart consists of four chambers, the upper two chambers called the atria and the lower two 
called the ventricles. The heart is a dual pump in which the left and right sides function as two separate 
pumps. The right side receives deoxygenated blood from the body and sends it to the lungs, while the left 
side receives oxygenated blood from the lungs and pumps it to the entire body. Since the left and right 
sides contain deoxygenated and oxygenated blood respectively; there exists a septum separating the two 
sides of the heart to prevent mixing of the blood from the left and right side. The heart contains four 
pressure-operated valves: the tricuspid valve which separates the right atrium and right ventricle, the 
bicuspid or mitral valve between the left atrium and left ventricle, the pulmonary semilunar valve between 
the right ventricle and the pulmonary artery, and the aortic semilunar valve between the left ventricle and 
the aorta. Each of these valves has a set of three flaps or leaflets, with the exception of the mitral valve, 
which has two. The edges of the atrioventricular (AV) valves are fastened by tough fibrous chords called 
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chordae tendineae, which in turn are attached to papillary muscles extending from the inner surface of 
ventricular walls. The chordae tendineae and papillary muscles work in unison to keep the AV valves 
closed during isovolumetric ventricular contraction (Sherwood, 2008).  
During each heartbeat, the four chambers of the heart contract and relax in a highly synchronized 
and organized manner to pump blood. The right atrium receives deoxygenated blood from the body 
through two large veins, the inferior and superior vena cava. The deoxygenated blood then enters the right 
ventricle through the tricuspid valve, from where it is eventually carried to the lungs by the pulmonary 
artery through the pulmonary valve. The oxygenated blood is returned to the left atrium by the pulmonary 
vein and then flows into the left ventricle through the bicuspid valve. Finally, the oxygenated blood is 
pumped out of the left ventricle through the aorta and distributed to all parts of the body (Sherwood, 
2008). Figure 2.1 shows the different parts of the heart and also outlines the direction of blood flow 
through the heart.  
 
Figure 2.1: Heart anatomy and directional blood flow (Sherwood, 2008) 
The heart wall is composed of three distinct layers: a thin outer layer of epicardium that covers 
the heart, a thin inner layer of endothelium and a middle layer of myocardium forming the bulk of the 
heart wall with its spirally arranged bundles of muscle fibers. The individual cardiac cells are 
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interconnected to form branching fibers, with the adjacent cells joined through intercalated discs. The 
intercalated discs consist of two types of cell-cell junctions: the desmosomes function as a mechanical 
connection between the adjacent cells and the gap junctions allow for action potentials to be transmitted 
from cell to cell. The presence of these gap junctions causes the interconnected cells to fire at the same 
time and contract as a single, functional syncytium.  A non-conducting fibrous skeleton surrounding the 
valves separates the atria and ventricles, such that the atria and ventricles each form a separate syncytium 
(Sherwood, 2008). 
2.2 Mechanical Function of the Heart  
The heart is a muscular pump that continuously pumps blood between the pulmonary and 
systemic circulation. The mechanical activity of the heart consists of alternating cycles of diastole 
(relaxation and filling) and systole (contraction and ejection). Each day the heart beats an average of 
approximately 100,000 times (~72 beats/min), completing about 2.5 billion relaxation and contraction 
cycles in a 70-year lifespan. Each day, the heart pumps about 2000 gallons of blood and thus, there is 5 
liters of blood in the systemic circulation at any given moment (AHA, 2011).  
The directional flow of blood through the heart chambers is controlled by pressure changes 
generated by the mechanical activity. Moreover, the cardiac output i.e. the amount of blood pumped by 
the heart every minute could vary depending upon blood pressure in the blood vessels and the chambers 
of the heart. For a healthy adult heart, normal peak systolic and diastolic pressures are 120mmHg and 
80mmHg respectively. The pressure in the atria remains more or less constant with slight variations 
between 0-8mmHg. Similarly, the aortic pressure is almost constant with moderate variations between the 
peak systolic and diastolic pressures. In contrast to the atria, the pressure in the left ventricle fluctuates 
dramatically between 0mmHg to slightly more than 120mmHg. This is because during diastole, the 
pressure in the ventricles must be lower than the atrial pressure and during systole it must be greater than 
the highest aortic pressure (Sherwood, 2008). Any condition, such as myocardial ischemia or infarction 
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due to CHD, that causes a change in these pressure distributions could result in insufficient mechanical 
function of the heart (Swan, 1979). 
2.3 Electrical Systems of the Heart  
The rhythmic mechanical pumping action of the heart is generated and maintained by the 
electrical activity of the heart. Heart muscle consists of two types of specialized cells: contractile cells 
constituting 99% of the heart muscle cells and autorhythmic cells that have pacemaker activity 
constituting the remaining 1% (Sherwood, 2008). Heart’s normal electrical activity originates in the sino-
atrial (SA) node located in the right atrial wall near the opening of the superior vena cava. The action 
potentials initiated in the autorhythmic cells of the SA node travel to the atria via the intermodal pathways 
and then through the atrio-ventricular (AV) node, bundle of His and Purkinji fibres to the rest of the heart 
resulting in coordinated rhythmic contraction of the different regions of the heart (Tripathi et al, 2011). 
Figure 2.2 shows the pathway of an excitation wave in the heart starting from the SA node. 
 
 
Figure 2.2: Electrical conduction system of the heart (Sherwood, 2008) 
The cardiac electrical cycle is initiated and maintained by the transmembrane flux of ions via ion 
channels, pumps and exchangers. The specific distribution of these ion channels determines the shape of 
the action potential and the conductance of the excitation wave in the heart (Tripathi et al, 2011). Under 
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normal conditions, the heart’s natural pacemaker (SA node) sets the rate of cardiac chamber contraction 
i.e. the heart rate. The cells of the SA node express the same genes as the contractile cells, but differ 
quantitatively in the expression of some ion channels, connexins, and transcription factors which generate 
automaticity in these myocytes (Mangoni, 2008).  
 The pacemaker cells of the SA node are capable of self-generating action potentials attributed to 
an inward current called the funny current (If), which is activated upon hyperpolarization in the diastolic 
range of voltages. The degree of activation of this current determines the frequency of action potentials 
causing the firing of the pacemaker cells. If is controlled by the levels of intracellular cAMP and thus, 
activated and inhibited by the ß-adrenergic and muscarinic M2 receptor activation respectively. The major 
constitutive subunits of f-channels in pacemaker cells are the HCN4 (Hyperpolarization-activated, cyclic 
nucleotide gated 4). The loss of these HCN4 subunits has been shown to cause rhythm disturbances 
(DiFrancesco, 2010). The strong If current initiated by hyperpolarization decreases the rate of K+ efflux 
and increases the membrane permeability to Ca2+ ions. Initially, the transient type voltage-gated (T-type) 
Ca2+ channels open and once the potential reaches the threshold, the longer-lasting type (L-type) voltage-
gated Ca2+ channels allow a large influx of Ca2+ ions resulting in action potential. The eventual 
repolarization is caused by activation of voltage-gated K+ channels and efflux of K+ ions. At negative 
potentials, there is a constant passive influx of Na+ ions into the pacemaker cells, since these do not 
contain voltage-gated Na+ channels (Mangoni, 2008). The normal rate of action potential discharge from 
the SA node results in 70-80 beats per min (Sherwood, 2008). Figure 2.3 shows the different phases 
during the action potential generation and repolarization of the pacemaker cells.  
17 
 
 
Figure 2.3: Action potential in pacemaker cells (Sherwood, 2008) 
The atrio-ventricular node (AVN), a small bundle of specialized muscle cells located at the base of right 
atrium near the septum, ensures a conduction delay between the atria and ventricles. It also helps protect 
the ventricular rhythm during atrial arrhythmias. The AVN is called the secondary pacemaker since it is 
endowed with automaticity and can effectively drive the heart rate at about 40-60 beats per min in cases 
of SA node failure or block (Sherwood, 2008). The Bundle of His is a tract of specialized cells originating 
in the AVN that enters the interventricular septum and branches into left and right bundle branches. At the 
apex of the heart, the Bundle branches contact the Purkinji fibers, which extend from the Bundle of His 
allowing for the fast propagation of an excitation wave generated upstream throughout the ventricular 
myocardium. The Bundle of His and Purkinji fibers can also pace the heart at the rate of 20-40 beats per 
min if the conduction in the AVN is blocked (Mangoni, 2008).  
 Unlike the autorhythmic cells, the action potentials of the contractile cells are initiated by the 
electrical activity propagated from the pacemaker cells. This activity cause the resting membrane 
potential (-90mV) of the contractile cells to rise rapidly due to the opening of the voltage-gated Na+ 
channels and consequently large influx of Na+ ions. The rapid depolarization causes an action potential 
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and is followed by a two-phase repolarization. The initial plateau phase of repolarization is maintained by 
a slow influx of Ca2+ ions through the L-type Ca2+ channels, while the rapid falling phase is caused by the 
increase in K+ efflux due to the opening of voltage-gated K+ channels (Sherwood, 2008). These phases of 
depolarization and repolarization can be seen in Figure 2.4. 
 
Figure 2.4: Action potential and conctractile response in cardiomyocytes (Sherwood, 2008) 
The electrical currents generated by the pacemaker cells that spread to all the contractile cells 
throughout the heart during depolarization and repolarization can be recorded on the body surface to 
produce an electrocardiogram (ECG). The P wave of the ECG represents atrial depolarization, the QRS 
complex represents the ventricular depolarization and simultaneous atrial repolarization and the T wave 
represents the ventricular repolarization. Any abnormalities in the heart rhythm can be detected by the 
deviations observed in the different segments of an ECG recording (Sherwood, 2008).  
2.4 Arrhythmia  
Cardiac arrhythmias, a type of heart disease involving an abnormal heart rhythm, can result from 
alterations in the SA node pacemaker activity or a blockage of electrical conduction downstream of the 
SA node. Arrhythmias can also result from the formation of a group of hyperactive cells called an ectopic 
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focus that fire at a rate greater than the SA node pacemaker cells (Sherwood, 2008). Brief arrhythmias do 
not affect the heart adversely, but prolonged arrhythmias could result in inefficient pumping of blood. 
Arrhythmias can be of different kinds: bradycardia is insufficient beating of the heart (less than 60 
beats/min); tachycardia is rapid beating of the heart (more than 100 beats/min); atrial fibrillation or 
quivering, which is characterized by rapid, irregular, uncoordinated depolarizations of the atria; or 
ventricular fibrillation or fluttering involving uncoordinated, chaotic contractions of the ventricles. Figure 
2.5 shows the difference between a normal heart rhythm and the heart rhythm during tachycardia. If left 
untreated, most arrhythmias could lead to heart failure (AHA, 2011).  Currently, such arrhythmias are 
treated by implantation of electronic pacemakers in the patients. In the United States alone, approximately 
358,000 electronic pacemakers are implanted every year. Almost all the pacemakers implanted are to treat 
bradycardia (Wood, 2002).  
 
Figure 2.5: ECG Signals (A) Normal PQRS wave (B) Rapid HR during tachycardia (Sherwood, 2008) 
2.5 Electronic Pacemakers 
The typical electronic pacemaker consists of two parts: the pacemaker unit and the wires that 
connect the pacemaker to the heart. The pacemaker unit consists of a battery and a controller, which 
monitors the patient’s underlying heart rhythm and accordingly delivers electrical signals at the required 
rate. The electronic pacemakers can either be single chamber, consisting of only a single wire connected 
to the heart, or dual chamber with two separate wires connected to the upper and lower heart chambers. 
The implantation of the pacemaker system is done under normal anesthesia with the pacemaker unit being 
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placed under the skin below the collarbone and the wires are placed through a blood vessel beneath the 
collarbone. The wires are properly positioned in the blood vessels using X-ray and finally connected to 
the pacemaker unit. The implantation surgery typically takes around 1-2 hours and the risk of 
complications is about 1-2%. Electronic pacemakers enable efficient pacing of the heart without any 
major disruptions to the patient’s mobility or daily activities (Wood, 2011).  
However, these pacemaker systems do present a number of limitations for long-term cardiac 
pacing. The main problems include replacement of generators due to limited battery life and problems 
associated with leads like fracture, displacement, inappropriate stimulation, loss of insulating material, or 
tissue perforation. All these disadvantages are exacerbated in the case of pediatric patients due to physical 
development and tissue ingrowth. Other possible complications include infection, thrombosis, 
maladaptive cardiac remodeling and lack of autonomic neurohumoral responsiveness (Cowan, 2011). 
2.6 Biological Pacemakers 
Electronic pacemakers are an effective treatment option for people with sinoatrial (SA) node 
dysfunction.  However, with their numerous limitations, electronic pacemakers are perceived only as a 
treatment rather than a cure.  (Cohen et al, 2005). Repeated operations are required to elongate and 
reposition the leads in pediatric patients.  In addition, the risk of heart failure may increase with long-term 
pacing (Freudenberger et al, 2005). 
In a healthy heart, the SA node is the main biological pacemaker, in which all ion channels and 
transporters needed to pace the heart reside in the sinoatrial nodal myocytes (Cohen et al, 2005).  The SA 
node also exhibits other important characteristics such as, the localization and congregation of SA node 
myocytes, strong mechanical and electrical integration into the cardiac tissue, the ability to initiate action 
potentials that are sufficient to propagate and regulate the rhythm of the heart, and capability to generate 
rhythm in the heart that responds to the physiological and emotional changes of the body (Rosen et al, 
2004).  The intrinsic characteristics of the SA node serve as fundamental guidelines for the designing of 
biological pacemakers. 
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Based on the characteristics of the SA node and the limitations, the perfect biological pacemaker 
should satisfy a number of criteria.  The biological pacemaker should be able to generate stable and 
spontaneous rate at physiological acceptable rate, it should be self-sustaining and require no battery or 
electrodes, it should pose no risks of inflammation and tumor growth at the implantation site, it should be 
immobilized at the implantation site and requiring no future replacement, it should have the ability to 
respond to changing philological and emotional demands of the body, and it should be at least as effective 
and reliable as electronic pacemakers (Rosen et al, 2004). 
In order to present a cure to cardiac rhythmic conditions, different types of biological pacemakers 
are proposed to mimic the natural cardiac pacemaker and to overcome the limitations and risks associated 
with electronic pacemakers.  A number of strategies can be implemented to initiate pacing of the heart 
including, up-regulating β-adrenergic responsive, decreasing outward current (Ik), increasing inward 
current (If), and introducing new pacemaker cells to the heart (Anghel, 2007).  Some strategies are not 
widely adapted due to their underlying disadvantages.  The up-regulated β-adrenergic receptors 
demonstrated higher heart rate during in vivo testing.  However, the overexpression of β-adrenergic 
receptors lacks long lasting effect, and the β receptor over expression may lead to other negative effects in 
the heart (Rosen et al, 2004).   The down-regulation of the outward current also has a number of 
limitations including prolonged action potential and irregularities in cardiac rhythms.  The strategy to 
increase inward current has been extensively studied because the method poses no effect on prolonging 
the action potential duration, and the inward current is well regulated by the autonomic nervous system 
(Qu et al, 2003).  Finally, the stem cell approach is to differentiate new pacemaker cells to exhibit the 
aforementioned characteristics. 
 Three methods were formulated to create and deliver a biological pacemaker, such as the 
injection of naked DNA, viral vectors, and cells into the heart (Cohen et al, 2005).  HCN 
(hyperpolarization-activated, cyclic nucleotide-gated) gene is used to overexpress the inward depolarizing 
current (If).  Direct exposure of naked DNA to the cardiac myocytes yields insufficient up-take rate and 
short duration.  Introducing viral vectors carrying the gene demonstrated much higher transfection 
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efficiency.  However, depending on the type of viral vectors used, they may cause immune response or 
tumor growth in the body.  The use of cells as carriers of the gene presents itself as a safer option as the 
genes are inserted using electroporation in vitro. 
2.7 HCN Transfected hMSCs as a Biological Pacemaker 
As a proof of concept, canine studies have demonstrated the effectiveness of HCN transfected 
myocytes in generating atrial beats via injection of adenovirus containing the gene into the heart (Qu et al, 
2003).  By transfecting stem cells in vitro, the risks associated with viral vectors can be avoided.   Having 
the ability to differentiate into multiple cell types such as bone, cartilage, muscle, tendon, and fat, 
mesenchymal stem cells are chosen for the biological pacemaker application for their multipotency.  
Adult mesenchymal stem cells are also desirable because they are readily available and abundant in adult 
patients.  Typically harvested from bone marrow, adult mesenchymal stem cells can be obtained from 
many parts of the body.  In clinical applications, these cells are also immunoprivileged, meaning they 
provoke minimal immune response from the host body (Rosen, 2004).  Combined with their low 
immunogenicity and high availability, adult human mesenchymal stem cells have the potential to provide 
an off the shelf cure for SA node dysfunction.  For patients who are not suitable to receive allogeneic 
cells, the mesenchymal stem cells could also be obtained from the patient’s own marrow. 
Adult human mesenchymal stem cells have demonstrated consistent ion channel properties.  In 
addition, these cells are also shown to form functional gap junctions among themselves and with 
cardiomyocytes both in vivo and in vitro (Rosen, 2007).  Given their multipotency, immonoprivileged 
nature, good availability, and gap junction formation with neighboring cells, adult mesenchymal stem 
cells are accepted as a promising platform for gene therapy.    
Rosen et al explored the use of adult human mesenchymal stem cells transfected with HCN genes 
for a biological pacemaker (2007). A normal sinoatrial nodal pacemaker cell is able generate its own 
depolarization and initiate an action potential that can be propagated to neighboring myocytes through 
gap junctions.  The flow of action potential continues to flow throughout the heart and results in the 
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controlled contraction of the atria and ventricles.  Whereas, in an adult mesenchymal stem cell that is 
transfected with the HCN gene, the inward current in the stem cell caused by the high resting potential of 
the adjacent myocytes would initiate a current flow to the adjacent myocytes, which ultimately depolarize 
and generate an action potential.  This action potential is then propagated down the conducting system of 
the heart (Rosen et al, 2007).  Essentially, the HCN transfected stem cell and adjacent myocytes act 
together as a pacemaker unit, as shown in Figure 2.6.  Unlike the natural pacemaker, the HCN transfected 
adult mesenchymal stem cells would not generate spontaneous heart rates by itself because it only 
functions as a source of depolarizing current to the neighboring myocytes, which generates the action 
potentials required to pace the heart.  The advantage of allowing the genetically modified stem cell and its 
adjacent myocyte to function synchronously as a single pacemaker unit is that no further work is needed 
to fully differentiate the stem cell into a pacemaker cell. 
 
Figure 2.6: hMSC vs. native pacemaker. (A) SA nodal cell working as a pacemaker unit. (B) HCN Transfected hMSC and 
cardiomyocyte working as pacemaker unit (Rosen, 2004). 
The performance of HCN transfected adult human mesenchymal stem cells is evaluated using in 
vitro and in vivo models (Rosen et al, 2004).  In practice, the HCN gene has a transfecting efficiency of 
around 40% using electroporation, which temporarily permeabilize the cell plasma membrane with an 
24 
 
external electrical field and allows the uptake of genetic material (Potapova et al, 2004).  For the in vitro 
model, adult mesenchymal stem cells are transfected with either HCN gene plus a fluorescent marker 
(GFP) or GFP alone.  The cells are then introduced to a monolayer of neonatal rat ventricular myocytes.  
After the formation of functional gap junction coupling, the myocytes in contact with the stem cells 
containing both the HCN and GFP beat significantly faster than the myocytes in contact with the stem 
cells expressing GFP alone, as shown in Figure 2.7 (Rosen et al, 2004).  In vivo model testing of the 
function of the HCN transfected adult mesenchymal stem cells using canine studies also yielded similar 
results.  In dog hearts that were injected with stem cells expressing both HCN and GFP, a higher average 
heart rate was recorded, originating from the injection site.  On the other hand, dogs that received stem 
cells expressing GFP alone demonstrated a considerably lower average heart rate, originating from 
multiple locations in the heart (Rosen et al, 2004). 
 
Figure 2.7: Action potentials of normal hMSCs (Top) and HCN2 transfected hMSCs (Bottom). The transfected cells beat 
much faster (Rosen, 2004). 
Although HCN transfected adult human mesenchymal stem cells demonstrate efficient pacemaker 
function with great clinical and commercial benefits, a number of major concerns remain to be addressed 
before they become viable treatment.  Due to the natural characteristics of the stem cells, there is a risk of 
tumor growth, cell migration, and differentiation into other cell types in the long term (Rosen, 2004).  
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These limitations not only reduce the pacemaker functions of the HCN transfected stem cells, they also 
pose serious health risks to the patients. 
2.8 Electrospun Scaffold 
To overcome the limitations of HCN transfected adult human mesenchymal stem cells, 
electrospinning can be used to create an scaffold that inhibits cell migration, maintains pacemaker 
function, and reduces the danger of tumor growth.  Electrospinning is an efficient and inexpensive 
manufacturing process that involves the use of a high electric force to extract a nanofiber from a charged 
capillary tip onto an oppositely charged colleting plate or drum, as shown in Figure 2.8 (Khil et al, 2003).  
Electrospinning is capable of producing a highly porous nanofibrous scaffold with good structural 
integrity (Pedicini, 2003).  For use in a biological pacemaker application, the electrospun matrix must 
have appropriate surface thickness and porosity to allow for the formation of gap junctions across the 
scaffold surface and the prevention of cell migration.  The electrospinning process allows for fine controls 
of different parameters of the scaffold such as fiber diameter, thickness, and mesh pore size by altering 
polymer solution concentration, applied voltage, working distance, and spin time (Khil et al, 2003). 
 
Figure 2.8: Schematic of electrospinning apparatus (Khil et al, 2003). 
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A range of polymers can be used to make electrospun scaffolds.  Polyurethane is widely used in 
production of tissue engineering scaffolds due to its good biocompatibility, manufacturability, mechanical 
properties, and wear resistance.  With good permeability to oxygen and water, polyurethane can maintain 
adequate diffusion of nutrients to cells in vivo (Khil et al, 2003).  However, additional structural support is 
required for an electrospun polyurethane matrix with the desirable thickness for biological pacemaker 
applications. 
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Chapter 3 Project Approach 
Before we could begin our testing and evaluation, we needed to define our design parameters and 
formulate a plan. This was accomplished through establishing objectives and constraints, identifying 
functions and specifications, and finally revising our client statement. With all of these parameters 
defined, we could proceed to testing and design validation. 
3.1 Initial Client Statement 
Based on the information gathered from our background research, we developed an initial client 
statement: 
To create a biocompatible scaffold that would inhibit migration of hMSCs while 
allowing for gap junction coupling with native cardiomyocytes. The device 
should also be easy to deliver. 
Through discussions with our advisor and client, we developed a list of objectives and 
constraints that would help us meet our project goals.  
3.1.1 Objectives  
The first parameter we needed to establish was design objectives. We defined “objective” as an 
aim or end of an action; something towards which effort is directed (Dym, Little, Orwin, & Spjut, 2009). 
With this in mind, we were able to formulate numerous objectives for our design.  
 Our design should be safe for the user, patient, and cells. It should not have any sharp objects 
protruding outward, ensuring the safety of the user and the patient. Additionally, it should limit cell 
migration to prevent loss of current density or tumor formation away from the implant site. The device 
must also be permeable to nutrients and cannot be cytotoxic.   
 The device should form gap junctions between all the cells present in the device and native 
cardiomyocytes. Gap junctions allow for ions to freely pass from cell to cell. In the case of the heart, gap 
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junctions allow smooth and synchronized pacing to occur. Therefore, gap junction formation is essential 
to the functionality of our device.  
Cells should be adhered to the device for delivery and implantation. This ensures patient safety as 
well as reliability of the device. If the cells are loose on the surface of the device, they could fall off 
during delivery or wander once implanted. This could lead to tumor formation or decrease the cell density 
on the device’s surface resulting in insufficient current density to pace the heart. 
 Ideally, there should be no synthetic divider between the hMSCs and the native myocytes. 
However, the device should not degrade until the hMSCs are completely immobilized so as to ensure 
stability in the connections between native and foreign cells. Additionally, wandering cells have the 
potential to be hazardous, so immobilization must be guaranteed. Thus, the device should last a 
substantial amount of time, before degrading.  
 Cyclic pulsing of the heart creates stresses that could result in fatigue failure of the device. The 
device must withstand normal cardiac forces and cyclic loading without greatly hindering normal 
mechanical and electrical function within the tissue. 
 Since the device is meant to pace the left ventricle, it must fit into either the ventricular septum or 
the left ventricular wall. Assuming that the heart is about the size of the human fist, the septum should be 
about 10cm in length and about 8mm in thickness. This means the device must be less than 8 mm long to 
prevent perforation of the septum during implantation. The ventricular wall is approximately 2-3 mm 
thick, so the device must be less than 2 mm long to prevent perforation of the heart wall. The attached 
cells will receive signals from the healthy native cells and restore normal pacing to the heart. Much of the 
data presented here is based on unpublished research conducted by Glenn Gaudette and his collegues. The 
data here is meant to serve as a rough average size rather than an absolute result. There is room for 
fluctuations and variances between patients. Other desirable objectives include a reasonable shelf life and 
ease of use.  
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3.1.2 Constraints  
 One of the most pressing constraints on this project is cost. All expenses associated with design, 
budget of $616. Additionally, the project must be completed March 2nd, 2012. Completion by this 
deadline will ensure that there is ample time to prepare the final product for presentation.  
 For the device to be worth using, it must be biocompatible and have low immunogenicity. 
Immune response, strong inflammatory response, or fibrotic encapsulation could all impede the 
pacemaker unit from functioning properly in situ.  
 The device must also stop the cells from migrating to other parts of the body. It must create gap 
junctions between native and implanted cells, and must be implantable within the myocardium.  The 
final step of planning involved mapping functions to satisfy the objectives and constraints, and 
determining means for achieving those functions.  
3.1.3 Functions 
To meet the defined objectives, the cells must adhere to the surface of the device, form gap 
junctions, and immobilize cells as described in the objectives section. Additionally, the electrospun matrix 
must promote cell viability to minimize cell density loss between seeding and implantation of the device. 
The device must be able to withstand the forces within the heart while minimizing the decrease in cardiac 
function. It must be implantable into the ventricular septum or left ventricular wall to enable gap junction 
formation between hMSCs and native cardiomyocytes.  
3.1.4 Specifications  
This section defines to device requirements quantitatively. A literature review determined that the 
optimal minimum cell count for a biological pacemaker is about 300,000 (Potapova et al, 2004).Using 
this number and cell density data collected in the lab using normal hMSCs, we determined a device cross-
sectional area of 12mm x 12mm to be sufficient for reaching 300,000 cells per device. To confirm 
functionality of the device, we will expect to see gap junction formation within the first 48 hours after 
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implantation. Taking into consideration all of the objectives, constraints, functions, and specifications, we 
could start planning on how we want to fabricate this device.  
3.2 Function Means Tree 
 A function means tree was used to visually map possible approaches to accomplishing the 
necessary functions. The functions mean tree is shown in Appendix C. 
3.3 Ranking of Design Requirements  
 An objectives tree, shown in Appendix B, was used to visually assess the objectives of the design 
as well as the subcomponents of each objective. This tree enabled the team to better understand the 
problem, which enabled us to tailor our design to the intricacies of the problem. After constructing the 
objectives tree, the first degree objectives were ranked (intellectual property, ease of use, easily 
implantable, etc.) using a pairwise comparison chart. Only first degree objectives that fell under 
the same primary objectives (safety, marketable, reliable, and functional) were ranked against 
each other.  
 The charts were made with the primary objectives on both the vertical and horizontal axis. Each 
objective on the vertical axis was ranked against the objective in the horizontal axis with a 1, 0, or ½. A 
box marked with a 1 indicates that the objective on the vertical axis is more important than the horizontal 
axis; A 0 indicates that the objective on the horizontal axis was more important than the vertical axis, and 
a ½ indicated that both objectives were equally important. The charts can be seen in Tables 3.1 to 3.4. 
Table 3.1: Safety Pairwise Comparison Chart 
Safe User Patient Cells Score 
User     
Patient     
Cells     
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Table 3.2: Marketability Pairwise Comparison Chart 
Marketable Cost Ease of 
Use 
Shelf Life First to Clinic Intellectual 
Property 
Score 
Cost       
Ease of Use       
Shelf Life       
First to 
Clinic 
      
Intellectual 
Property 
      
 
 
Table 3.3: Reliability Pairwise Comparison Chart 
Reliable Structural Integrity Failure Rate Score 
Structural Integrity    
Failure Rate    
 
Table 3.4: Functionality Pairwise Comparison Chart 
Functional Gap 
Junction 
Cell 
Adhesion 
hMSC 
Immobilization 
Encase 
Cells 
Easily 
Implantable 
Close to 
Myocardium 
Manufacturing 
Feasibility Score 
Gap Junction         
Cell Adhesion         
hMSC 
Immobilization 
        
Encase Cells         
Easily 
Implantable 
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Close to 
Myocardium 
        
Manufacturing 
Feasibility 
        
 
The completed tables from the four team members and the client were tallied and put into Table 3.5. 
 
Table 3.5: Pairwise Comparison Results 
Safety Functional Reliable Marketable 
Objective  Score Objective  Score Objective  Score Objective  Score 
Patient 9 
hMSC 
Immobilization 
18.5 
Structural 
Integrity 
3.5 Ease of Use 13.5 
Cells 4.5 
Gap Junction 
Formation 
17.5 Failure Rate 1.5 IP 12.5 
User 1.5 
Close to 
Myocardium 
14.5     
First to 
Clinic 
9.5 
  
Manufacturing 
Feasibility 
10.5     Shelf Life 8.5 
  Cell Adhesion 10     Cost 6 
  Encase Cells 7        
  
Easily 
Implantable 
3      
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3.4 Revised Client Statement 
The information gathered during the planning stages was used to revise our initial client 
statement. Using our objectives, constraints, functions, and specifications, a revised client 
statement was created: 
To create a biocompatible device to deliver hMSCs that would inhibit the migration of 
hMSCs while allowing for gap junction coupling with native cardiomyocytes. The device 
should also be fairly easy to deliver and must promote cell adhesion to the device surface. 
Implanted hMSCs must be immobilized at the implant site and must pace native 
myocytes. A minimum scaffold surface area, to be determined through experimentation 
and cell viability, must be achieved in order to produce sufficient cardiac pacing. The 
device should also provide sufficient mechanical support to withstand cardiac forces and 
maintain cell viability. It must also be implantable within close proximity of native 
myocytes while minimizing decrease in mechanical function and maintaining natural 
conductivity in the heart. 
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Chapter 4 Alternative Designs  
For the purposes of determining a proper design to satisfy the desired functions and objectives, 7 
preliminary designs were devised. These designs were evaluated on several criteria to determine 2 
alternative designs. Finally, these alternative designs were compared to determine 1 final device design.  
4.1 Needs Analysis 
In order to provide ourselves with multiple functional designs for testing, we closely examined 
the revised client statement, objectives, constrains and functions of the project.  Regardless of the 
effectiveness and efficiency of the designs, all designs of the device must satisfy the project constraints.  
As mentioned in chapter 3, the designs must be cost effective, safe for the patients and the users, 
sufficiently compact to be implanted into the heart, allowing the formation of gap junction coupling, and 
preventing cell migration.   
 From the pairwise comparison chart, the team rated each of the primary functions that the 
pacemaker device should satisfy.  After compiling all the scores, hMSC immobilization is deemed the 
most important among all the primary functions.  With device safety being our most important objective 
and constraint, the immobilization of hMSCs is the corresponding function that ensures the safety of the 
device for the patients.  This function arises from the basic limitations of using HCN transfected hMSCs 
for pacing.  Chapter 4 extensively explained the safety concerns of using stem cells for pacing.  
Compared with conventional electronic pacemakers, the use of stem cells in pacing has the potential risks 
of rejection, inflammation, tumor growth, cell migration, and uncontrolled differentiation into other cell 
types.  Therefore, every design should not allow any cell migration for the safety of the patients. 
 Formation of gap junctional coupling is evaluated as the second most important function for the 
biological pacemaker.  It is the most important function other than safety because function gap junction 
formation is required by the HCN transfected hMSCs for pacing of a heart.  Specifically, Rosen et al 
found that gap junctional coupling between the stem cells and the surrounding myocytes must be 
sufficient to depolarize the adjacent myocytes (2004).  Therefore, there is no optimal percentage of gap 
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junction formation, the more the gap junctional coupling; the more efficient and effective the pacemaker 
unit would be. 
 Rosen et al demonstrated that HCN transfected hMSCs injected into the canine hearts initiated 
action potential from the injection site only, and propagated throughout the heart for pacing (2004).  Since 
myocardium is the tissue that is responsible for contraction of the ventricles, it is determined that the 
biological pacemaker should be implanted as close to the myocardium as possible.  Consequently, the 
design of shape, size, and mechanical properties of the biological pacemaker scaffold are extensively 
affected by this function.  
 Manufacturing feasibility, cell adhesion, cell encasement, and ease of implantation are the other 
primary functions that the pacemaker should satisfy.  Among these, manufacturing feasibility is deemed 
to be the most important because it determines the cost and the feasibility of the entire design.  This 
function also affects the shape and complexity of the scaffold design.  Lastly, easily implantable was 
determined to be the least important primary function.  With this novel method of using stem cells for 
pacing of the heart, the device design should ensure effectiveness and efficiency before allowing for easy 
implantation for the surgeons. 
Two delivery methods were also examined for the ease of delivery of the biological pacemaker.  One 
method was the suture based delivery method, in which a surgical suture needle would be used to guide 
the insertion of the biological pacemaker.  Prior to delivery, one end of the scaffold would be heat shrink 
to the blunt end of the needle.  The second method would be the catheter based delivery method, in which 
a catheter designed previously by an MQP group for the delivery of microthreads would be used.  Similar 
to the delivery of microthreads, the biological pacemaker would be draped over the inner core for easier 
insertion.  As shown in Figure 4.1., after the outer needle is inside the myocardium, the outer needle 
would be pulled back while the inner core deploys the biological pacemaker.  The catheter based delivery 
mechanism was designed to reduce shear on the scaffold as it passes under and through the myocardial 
surface (Costa et al, 2011). 
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Figure 4.1: Staged deployment of catheter (Costa, 2011) 
 
4.2 Preliminary Designs 
 
 
Figure 4.2: Preliminary Design 1 
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Preliminary design 1 focuses on a doughnut-like cylinder with a hollow, or open, core. The top 
left design is a basic circular design where the cells would be seeded in the blue ring region. The bottom 
left and top middle designs are almost identical to each other. The only difference between the two is the 
positioning of the “teeth” represented by the eight rectangular protrusions on the outside and inside of the 
ring, respectively. The bottom right design combines the previous two designs to create better fixation. 
The far right design is a spinoff of the bottom right design. The only difference is that the ring region will 
not seed the cells, but instead act as support for the chambers of cells.    
 
Figure 4.3: Preliminary Design 2 
Preliminary design 2 is consisted of supporting rods aligned in a unidirectional arrangement on a 
sheet of porous scaffold.  The rods can be placed on the collecting plate before the electrospinning 
process.  As a result, electrospun nanofibers should accumulate directly on top of the rods.  Next, HCN 
transfected hMSCs could be seeded on either side of the sheet.  The sheet would then be folded into a 
rectangular shape after cell attachment, sandwiching the cells in the middle.  The edges could be sealed 
using heat shrink. 
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Figure 4.4: Preliminary Design 3 
Preliminary design 3 is consisted of a tubular construct outer layer and a solid inner core.  The 
outer layer can be easily made using electrospinning with a collector drum.  Due to the flexibility in the 
fabrication technique, the inner and outer diameter of the tubular construct can be easily controlled and 
altered.  The cells would be seeded in the empty space between the two layers.  The two ends would be 
sealed using heat shrink.  The tubular shape of this design allows for easier insertion into the myocardium 
when compared with the rectangular design. 
 
Figure 4.5: Preliminary Design 4 
Preliminary design 4 is a combination of previous two designs.  Due to low seeding density 
within the tubular construct, the cells would be seeded on a flat sheet of porous scaffold.  After cell 
attachment, the sheet would be rolled into a tubular shape for ease of implantation. 
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Figure 4.6: Preliminary Design 5 
Similar to preliminary design 2, this design is another rectangular shaped scaffold that allows for 
high seeding density on a flat surface.  Supporting rods are aligned between the two layers of the scaffold 
for structural integrity and structural support.  Heat shrink can be used to seal the four edges of the device 
before implantation. 
 
Figure 4.7: Preliminary Design 6 
Preliminary design 6 is a spinoff of design 1. It is a much more complicated design where the ring 
region can be broken down into three different layers. The first layer is the outer layer (indicated in 
black). This is composed of polyurethane and would give the device structural support. The second layer 
is the middle coating (indicated in yellow). This would be a coating of some polymer that would promote 
cell adhesion to the device. The final layer is the cell seeding region (indicated in red). This is where the 
cells would be seeded and, hopefully, stay immobilized thanks to the coating.  
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Figure 4.8: Preliminary Design 7 
Preliminary design 7 incorporates the structural rigidity of the rod-supported designs with the 
ease of implantation of the tubular design.  The outer scaffold contains a mesh-like backbone for 
mechanical support.  The internal metallic mesh can be installed to the collector drum.  During 
electrospinning, nanofibers are then layered on top of the mesh to create a porous scaffold. 
4.3 Alternative Designs 
Based on the results of our initial feasibility studies pertaining to our preliminary designs, we 
narrowed down to two alternative designs. These alternative designs are essentially a modification of the 
preliminary designs 5 and 7 as shown in chapter 4.  
Alternative Design 1 is a modification of the preliminary design 7. This design will involve a 
cylindrical mesh-like fibrin support structure, which would be pre-made and installed on the small 
diameter collecting drum before electrospinning the scaffold material onto it. During electrospinning, the 
PE/PU fibers will be layered over the fibrin mesh to create a porous scaffold. The resulting scaffold once 
removed from the mandrel and processed further according to the existing protocol, by placing in the 
water and ethanol baths, would retain its added structural integrity provided by the fibrin support 
structure. The core of this scaffold will be hollow and cells will seeded onto inner circumferential areas. 
Once the cells are seeded along the entire surface area, the ends would be sealed using a custom heat 
shrink method. The diameter and length of this construct will be determined depending on the seeding 
density of the cells onto the final construct and cell viability after the ends are sealed off using heat 
shrink. 
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Figure 4.9: Design Alternative 1 
Alternative  design 2 is a modification of the preliminary design 5, which is a rectangular shaped 
scaffold allowing for higher seeding density as compared to that on a cylindrical construct. This seeding 
density data has been obtained from the Myocardial Regeneration Lab at WPI. But instead of starting 
with a flat sheet, this rectangular scaffold construct will be obtained from the fibrin supported cylindrical 
construct as described in the alternative design 1. Once the large diameter cylindrical scaffold is removed 
from the mandrel along with its fibrin support structure, the scaffold will be cut open into a flat sheet. Cell 
seeding will be performed on this flat fibrin-reinforced scaffold, since higher seeding densities have been 
reported on flat sheets as compared to cylindrical constructs. After the cells are seeded on the upper side 
of this scaffold sheet, it will be folded over like a sandwich with the seeded cells on the inner side. 
Finally, the three open ends of this folded construct will be sealed using a custom heat shrink method. 
The modification made to the preliminary design 5 in terms of using a meshed fibrin support structure 
instead of parallel rods, will provide better structural and mechanical integrity. Also, we propose to obtain 
the flat sheet from a cylindrical construct since it was suggested that electrospinning on a cylindrical 
mandrel results in more uniform porous structure of the scaffold. Just as with the alternative design 1, the 
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exact dimensions of the resulting final scaffold sheet will be determined depending on the cell viability 
after the ends of the sheet are sealed off using heat shrink. 
 
Figure 4.10: Alternative Design 2 
4.4 Feasibility Study 
With manufacturability being one of the most important functions of the design, extensive 
feasibility study needs to be performed to mimic different steps of the manufacturing process and to test 
material properties of the device.  When compared with designs from previous years, the major 
advancement of our designs is the incorporation of fibrin microthreads as supporting structure for the 
delicate cardiac scaffold.  In order to ensure the feasibility of incorporating new elements to existing 
electrospinning protocol, simple experiments would be conducted using fibrin threads to test for their 
dissolution property and ease of preparation for electrospinning.  In addition, since head shrink would be 
used to seal the edges of the device, it is crucial to determine the affected area of damaged cells by the 
heat.   
During the initial steps of the electrospinning process, polyurethane would be dissolved to a 
liquid form using a predetermined solvent.  The solvent would then be removed from the electrospun 
scaffold by soaking the material in two consecutive solvent baths comprised of water and ethanol.  
Therefore, in order to incorporate fibrin threads to the electrospun scaffold as a supporting material, the 
fibrin threads must not dissolve in either water or ethanol and retain its mechanical strength after the 
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liquid baths.  A simple dissolution test was performed using dry fibrin threads, which mimic the actual 
condition of the threads after electrospinning.  A strand of fibrin thread was cut into multiple shorter 
pieces and laid in two separate petri dishes.  Either water or ethanol was then added to each petri dish till 
all pieces of the fibrin threads were fully submerged.  Since the electrospun scaffold would be soaked in 
each solvent bath for 20 minutes in room temperature according to the existing protocol, the threads was 
also submerged in the solutions for 20 minutes under the same conditions.  After the 20 minute period, 
the threads was removed from the liquids and allowed to be air dried for five minutes.  Afterwards, the 
threads were pulled using tweezers, and the forces required to break the saturated threads were compared 
with the forces used to break dry threads.  The dissolution test showed that the fibrin threads did not 
dissolve in either water or ethanol, and no significant changes in the mechanical strength of the threads 
were observed.  Therefore, the test validated the feasibility of using fibrin threads as the supporting 
material for the electrospun scaffold. 
After demonstrating the feasibility of incorporating fibrin threads to the electrospinning process, 
we further tested the ease of preparations required to sufficiently attach and align the threads onto the 
collecting rod.  Ideally, we would want the process to be as flexible as possible by using already made 
and dried fibrin threads instead of using freshly made threads that have not yet to dry.  First, we tried 
saturating dry threads with water, and then attach them to the rod using water’s capillary force.  However, 
saturated fibrin threads proved to be too stiff even after being saturated.  This resulted in difficulties 
wrapping the treads consistently and accurately around the rod, and detachment of the threads from the 
rod as water evaporates from the surface.  As an alternative method, we attempted to use freshly made 
fibrin threads before they have been dried.  After the threads were pulled from the fibrin bath, the wet 
threads were immediately adhered to a slowly spinning rod in helical and anti-helical directions, which 
resulted in the formation of a fibrin web covering the surface of the rod.  When compared with the dry 
threads, the wet threads were much more flexible, which resulted in much higher accuracy in maintaining 
appropriate spacing between the threads, and the threads were able to stay adhered to the rod.  In addition, 
ease of removing the fibrin mesh was also determined.  After complete drying of the fibrin mesh on the 
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collecting rod, the fibrin mesh was saturated in water to allow for some degree of flexibility during the 
removal.  When attempting to remove the mesh, the fibrin mesh was peeled off with only minimal force 
and there was no chemical bonding between the fibrin mesh and the collecting rod. 
Head shrink was proposed to be used as a method of sealing the exposed edges of the folded 
scaffold to prevent cell migration.  The method was chosen to be the preferred sealing method because of 
the theoretical ease of controlling the scaffold size by modifying the size of heat press.  However, 
extremely high temperature is required to fuse electrospun polyurethane, and the high temperature used 
has detrimental effect on the viability of the cells.  Therefore, to compensate for the reduced cell count 
within the scaffold, the area and number of cells affected by the heat shrink of the scaffold edges must be 
determined.  To perform the study, hMSCs would be seeded onto one side of the electrospun scaffold and 
cultured for seven days to allow for cell attachment.  Then the scaffold would be folded inward, 
sandwiching the cells in the middle before the heat shrink.  A custom made heat press with the 
predetermined dimensions would be used to seal the three exposed edges of the scaffold.  Afterwards, the 
sealed scaffold would then be fixed and sectioned.  The sections would be stained with live/dead staining 
and observed under the microscope for affected area and damaged cells.  By knowing the affected area 
and number of damaged cells, we can compensate by increasing the surface area of the scaffold. 
4.5 Decisions on Final Design  
 In choosing between the alternative designs, two major factors were considered to determine the 
best candidate. Seeding densities for cylindrical and flat polyurethane scaffolds were previously 
determined in research done by Nancy Duffy. For a tubular construct 2 cm in length and 1 mm in 
diameter, a cell count of 1100 cells could be achieved. Because of the resulting low seeding density in 
tubular designs and considering the need for approximately 150,000 cells, it is unrealistic to pursue this 
design. For a flat polyurethane sheet design, approximately 1200 cells could be seeded per mm2, making 
the desired cell count feasible with a design that is 1.5 mm x 10 cm in area when unfolded. When folded 
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for delivery, the total exposed area still meets the minimum requirement for surfaces enabling cell to cell 
contact.  
 Additionally, the deliverability of the two designs had significant effect on the final decision. It 
was determined that, if feasible, a catheter-based delivery method is highly advantageous compared to a 
suture-based method. Using a previously designed catheter as a model, it was determined that the inner 
catheter diameter would require an outer cylindrical scaffold diameter too small to produce the desired 
cell numbers. However, for a flat sheet design, it was determined that even when folded over itself, the 
sheet could still be made to fit inside the 1 mm inner diameter of the scaffold while still meeting the 
required exposed area and seeding density.   
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Chapter 5 Methods and Results 
5.1 Determination of the Scaffold Surface Area 
 
Before fabricating the design of our scaffold, it was imperative to determine the minimum surface 
area needed to encapsulate the required number of cells for effective pacing of a human heart, while 
allowing for implantation through a minimally invasive procedure. Using the transfection efficiency of 
about 60% for HMSCs as obtained from literature (citation), a retention rate of 10% and a safety factor of 
2, it was determined that around 150,000 cells would be required for efficient pacing out of the total 
1,000,000 injected cells. Also, using the seeding density of 1254 cells/mm2 on a flat sheet scaffold as 
determined previously (citation), the minimum scaffold surface area was calculated to be 1.2cm2. This 
area translated into a scaffold sheet with dimensions 40mmx 1.5mm for easy implantation through a 
catheter.  
5.2 Mandrel 
 
 Using a schematic supplied by Saif Pathan, Biosurfaces Inc., two mandrels were constructed. 
These were used as a base to electrospin the desired scaffolds. Each mandrel is made from stainless steel 
with a length of 30.48 centimeters (1 foot) and a diameter of about 3 centimeters (1.25 inches). Figure 5.1 
shows both mandrels fully assembled.  
47 
 
 
Figure 5.1: Constructed mandrels based on Biosurfaces schematic 
The spin time used to create the scaffold is a major contributor to thickness and pore size. 
At a spin time of 30 minutes, the scaffold proved to be too thick. While the pore size passed the 
migration test, a thinner scaffold is most desirable in order to maximize the cell to cell 
interactions without losing the strength. Once this was determined, a spin time of 15 minutes was 
tested. Figure 5.2 below shows the control scaffold with a 15 minute spin time. 
 
Figure 5.2: 30 minute control scaffold 
Fibrin threads were placed on the mandrel to increase the strength of the material as 
structural integrity tends to decrease with shorter spin times. Figure 5.3 shows a mandrel 
wrapped with fibrin threads. 
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Figure 5.3: Fibrin threads on bare mandrel 
Anticipating that the threads would not be easily removed from the mandrels, Teflon tape 
was wrapped around one of the mandrels. It was speculated that Teflon tape would reduce the 
fibrin threads adherence to the mandrel making removal of the scaffold with fibrin threads easier. 
Figure 5.4 below shows a Teflon tape wrapped mandrel with fibrin wrapped around the surface. 
 
Figure 5.4: Fibrin threads on Teflon coated mandrel 
After the material was made and removed from the mandrels, it was noted that the fibrin 
did not adhere to the scaffold in either mandrel. Additionally, it was observed that the fibrin 
threads seemed to damage the material as it was being removed from the mandrel. So, the fibrin 
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which was supposed to help strengthen the scaffold actually made it weaker. Figure 5.5 below 
shows the resulting scaffold from the plain mandrel with fibrin wrapped around it. 
 
Figure 5.5: Scaffold from fibrin coated bare mandrel 
Also, the Teflon coated mandrel produced a scaffold that was thicker in some regions 
than others. This resulted in a spotted pattern. Figure 5.6 shows the resulting scaffold from the 
Teflon wrapped mandrel with fibrin attached to the surface. 
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Figure 5.6: Scaffold from Teflon coated fibrin mandrel 
However, this setback proved to be a breakthrough in terms of strength. If the spotted 
regions could be manipulated so that the scaffold displayed patterns of thinner and thicker 
material, then the strength and thickness problem could be solved. To test this theory, four 
distinct patterns of Teflon tape were made on the two mandrels. The first pattern completely 
covered the mandrel leaving no stainless steel visible. The second pattern on the same mandrel 
formed a spiral that lead from about half way down the mandrel to the end. In this pattern, the 
Teflon was manipulated so that a thin layer of stainless steel was visible in a spiral pattern. The 
first pattern on the second mandrel formed stripes along the length of the mandrel. Like the 
second pattern on the first mandrel, a thin layer of stainless steel was visible. The second pattern 
on the second mandrel formed a helical structure that consisted of four pieces of Teflon tape. 
This pattern left a much larger amount of stainless steel visible. Figure 5.7 shows both mandrels 
with all four designs made out of Teflon tape. 
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Figure 5.7: Teflon designs on mandrels 
The completely covered region reproduced the spotted pattern from the first spin with 
Teflon. Figure 5.8 below shows the resulting scaffold from this pattern. 
 
Figure 5.8: Scaffold from completely coated Teflon mandrel 
 
 The spiral patterned Teflon region produced a scaffold with evenly distributed regions of thicker 
and thinner material. Figure 5.9 shows the resulting scaffold from this pattern. 
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Figure 5.9: Scaffold from spiral Teflon design 
The striped patterned Teflon region also produced a scaffold with distributed regions of thicker 
and thinner material, but the regions were not as evenly distributed. Figure 5.10 below shows the resulting 
scaffold from this pattern. 
 
Figure 5.10: Scaffold from stripe Teflon design 
The helical patterned Teflon region produced a scaffold with more square regions of thicker 
material with thinner crossed lines. Figure 5.11 shows the resulting scaffold from this pattern. 
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Figure 5.11: Scaffold from helical Teflon design 
5.3 Patterned Scaffold Fabrication 
 
Coating the mandrel with Teflon tape resulted in the formation of a patterned scaffold with thick 
and thin regions, but it was difficult to adhere the Teflon tape onto the mandrel to form intricate patterns. 
An intricate square pattern (1.5mmx1.5mm) was laser cut onto an adhesive polyester sheet using a 
Universal Laser Systems VLS4.60 with a 10.6 µm CO2 laser attachment. The patterned sheet was adhered 
to a bare metal mandrel and acrylic lacquer was spread on the grooved surface. Excess lacquer was 
removed and the adhesive sheet was removed after 5 minutes of curing. The lacquer was cured overnight 
leaving a permanent pattern on the mandrel. BioSurfaces, Inc. electrospun a polyurethane and 
polyethylene terapthalate blended solution over the mandrel for 30 minutes. The patterned scaffold was 
obtained after washing in water and ethanol. The obtained electrospun scaffold in this case was intricate 
with desired thick and thin regions as can be seen in Figure 5.12, but the paint tended to stick onto the 
scaffold itself while removal.  
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Figure 5.12: Acrylic patterned mandrel (left) and 30 minute electrospun sheet produced by acrylic patterned mandrel 
(right) 
Next, an epoxy material was used to coat the mandrel with the intricately patterned transparency 
sheet. Following the same procedure as with acrylic lacquer, the adhesive sheet was removed and the 
epoxy was left to cure overnight to produce a pattern on the mandrel as seen in Figure 5.13 below.  The 
PU/PET blended solution was then electrospun on the mandrel for 60 minutes. The use of epoxy 
eliminated the problem of the paint sticking onto the scaffold, but the difference in the width of the thin 
and thick regions of the resulting scaffold was reduced as can be seen in Figure 5.13. 
 
Figure 5.13: Epoxy patterned mandrel (left) and 60 minute electrospun sheet produced by epoxy patterned mandrel 
(right) 
5.4 Migration Testing 
 
With the electrospun blend of PU/PET, it was imperative to determine the average pore size in 
the resulting scaffold. This was essential because one of the main functions of the scaffold is to prevent 
the migration of HMSCs from the implant site to the other areas of the heart. The average diameter of 
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HMSCs is about 10µm and they can also deform under physiological conditions. Taking these two factors 
into consideration, it was deemed appropriate that the scaffold, spun at 15mins spin time with a thickness 
of approximately15µm, should have an average pore size of less than 5µm.  
The pore size of the scaffold was determined by conducting migration testing using colored 
microspheres of 5µm diameter. A section of the scaffold (1.7mm x 1.4mm) was cut and placed on the 
mesh of a Gaudette- Pins well. Once tightly secured within the well, the entire well was placed in a petri 
dish. For the first round of testing, the microspheres solution with a starting concentration of 1.3x108/ml 
was diluted 100-fold in deionized water. This dilution factor was calculated by determining the average 
number of cells that would be present on that size of scaffold section, taking into account the average 
number of cells (~200,000) to be held in our final scaffold design and the seeding density of cells onto the 
scaffold (~1200 cells/mm2),  200µl of diluted microsphere solution was then poured into the Gaudette-
Pins well with the secured scaffold section and allowed to sit for 15 minutes shown in Figure 5.14. 
 
Figure 5.14: Scaffold section clamped in a Gaudette-Pins well with the microsphere solution at 100-fold dilution poured 
on the top side 
The scaffold section was retrieved from the well, carefully placed on a slide, and covered with a 
coverslip. This section with the microspheres side on the top was viewed under the microscope. Later, the 
scaffold section was flipped upside down and viewed under the microscope. It was observed that a 
comparatively larger number of microspheres were visible on the top side of the scaffold where the 
microsphere solution was poured in comparison to the bottom side. However, the microspheres were hard 
to identify and could not be visualized under the microscope. Still, in certain areas of the scaffold there 
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were tears. Here, the microspheres could be seen more clearly. In those areas, more microspheres seemed 
to have migrated from the top to the bottom side of the scaffold. 
For better visualization of the microspheres’ migration, this experiment was repeated with a more 
uniform section of the scaffold and a dilution factor of 1/2 for the microspheres solution. Also, a higher 
volume (400µl) of diluted solution was poured onto the middle of the secured scaffold section in the 
Gaudette-Pins well. The higher volume was used so as to be able to test the supernatant for the presence 
of microspheres. The green color of the solution was clearly visible at this concentration showed in Figure 
5.15 below.   
 
 
Figure 5.15: Scaffold section clamped in a Gaudette-Pins well with the microsphere solution at 1/2 dilution poured on the 
top side 
When viewed under the microscope after 15 minutes, a very large number of green circular discs 
were clearly seen on the top side of the scaffold shown in Figure 5.16 below. The density of microspheres 
on this side of the scaffold was so high that the individual fibers of the scaffold could not be seen. In 
contrast, the bottom side showed the presence of nearly no microspheres with a slight shadow indicating 
microspheres on the other side of the scaffold and shown in Figure 5.17. The supernatant left behind in 
the petri dish was also seen under the inverted microscope for the presence of microspheres. No 
microspheres were visible in the supernatant shown in Figure 5.18. 
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Figure 5.16: Top view of the scaffold section with microspheres (left) taken at 40x and (right) taken at 100x oil                
bar = 25µm 
 
Figure 5.17: Bottom view of the scaffold section (left) taken at 40x (right) taken at 100x oil, bar =25µm 
 
Figure 5.18: Supernatant showing the presence of no microspheres taken at 20x (left), Microspheres on a glass slide taken 
at 40x (right), bar=25µm 
58 
 
Further migration testing with microspheres was performed on the new scaffold designs 
incorporating the thick and thin regions of the material obtained by Teflon coated mandrel. A section of 
the patterned scaffold was secured in a Gaudette-Pins migration well and a mixture of microspheres and 
DI water in 1:1 ratio was pipetted onto the scaffold. Once the subnatant fluid was accumulated below the 
migration well, it was imaged alongside the top and bottom surfaces of the scaffold for the presence of the 
microspheres. The subnatant from the patterned scaffold spun at 15 mins as seen in the Figure 5.19A 
shows the presence of microspheres. This was due to imperfections in the scaffold as seen in the Figure 
5.19B with large pores between the scaffold fibers. Thus, the teflon coated scaffold spun at 15 mins failed 
to prevent microsphere migration.  
 
 
Figure 5.19: Subnatant from a 15 min teflon patterned scaffold showing the presence of microspheres taken at 20x (left, 
Figure A), Teflon patterned scaffold spun at 15 min showing imperfections (right, Figure B) 
The same migration testing was performed on the patterned scaffold obtained after 30 mins of 
electrospinning on the acrylic-coated mandrel and produced similar results as seen in Figure 5.20. 
A B 
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Figure 5.20: A) 30 min acrylic patterned scaffold with imperfections in the thin regions shown by the arrows [red]. B) 
Positive control of subnatant with arrows [green] pointing to microspheres. C) Negative control with DI water only. D) 
Subnatant of 15 min flat scaffold showing no microspheres. 
Finally, migration testing was performed on an epoxy patterned scaffold spun at 60 minutes. It 
can be clearly seen in Figure 5.21 below that the subnatant from the sample scaffold showed no presence 
of microspheres. So, the 60 min epoxy patterned scaffold was successful in preventing microsphere 
migration.  
 
 
Figure 5.21: Positive control with microspheres (left, Figure A), Negative control with DI water (middle, Figure B), 
Subnatant of 60 min epoxy patterned scaffold showing no microspheres (right, Figure C) 
A B C 
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5.5 Heat Sealing 
Once it was determined that heat sealing would be the best method for bonding the edges of the 
scaffold to each other, a functional heating element had to be created. The initial design of a heating 
element, shown in Figure 5.22, consisted of a 9 volt battery with positive and negative leads running to 
opposite ends of a copper wire mounted between two finishing screws. Power was regulated with an 
on/off switch.  
 
Figure 5.22: Preliminary heating element 
Testing of the first device was done with folded 50 µm thick pieces of scaffold. Power was turned 
on and the unit was tested at standard time intervals. Initial testing was conducted to determine if the 
heating element could melt the scaffold at each time point. Data from this experiment is shown in Table 
5.1 below. 
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Table 5.1: Time connected to the battery 
Time On (s) Melting (Y/N) 
5 N 
10 N 
30 N 
60 N 
120 N 
180 N 
 
A second heating element, shown in Figure 5.23, was designed using a 12 volt 18 amp computer 
power supply unit (PSU). This unit consists of positive and negative leads each of which is connected to 
an end of a steel wire 4.5 cm in length. Because PSU’s are designed with a switch that prevents the supply 
from running after a short circuit, an additional switch was added to circumvent this failsafe.  
 
 
Figure 5.23: Second iteration heating element 
Because this second design did not have a continuous flow of power, the same initial test was 
conducted using “number of clicks” of the power switch as the independent variable instead of time. Once 
again, testing was done first to see if melting was possible. This experiment was done with 50 µm folded 
scaffold pieces. The data from this experiment is shown in Table 5.2 below.  
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Table 5.2: Number of clicks relative to scaffold sealing 
# of Clicks Melting (Y/N) 
1 N 
2 N 
3 Y 
4 Y 
5 Y 
A third iteration of the heating element was designed so that a scaffold could be brought near the 
heated surface gradually to avoid catastrophic failure of the polymer mesh by overheating. This design 
used the same PSU and positive and negative leads. Because a wire complicated sealing of the edge of 
scaffold which is less than 50 µm thick, it was replaced with a 1”x8” copper ribbon. This ribbon would 
allow the edge of the scaffold to be pressed against the heater to make sealing easier and more precise.   
Folded 15 µm samples were tested at different intervals of distance and time to optimize distance from the 
heating element and time under heat.  
A final iteration of the device was made using a power supply provided by Worcester Polytechnic 
Institute. The new power supply allows for controllability of voltage and current going into the resistance 
heater. This allows for variation in temperature, allowing for optimization of temperature to be 
determined. The final design, shown in Figure 5.24 below, consists of two acrylic bases connected by 
steel rods. A 4” strip of copper tape is connected to the end of the rods by polymer weld. 
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Figure 5.24: Final base design for heating element 
An alternative design was drafted with the intention of having a heat press which could 
simultaneously heat and seal 4 edges of the device while cutting out the shape of the scaffold. However, 
this design was deemed too difficult to manufacture with the resources available in the WPI machine shop 
within the time constraint of the project.  
To systematically test the effect of distance from heating source and temperature of the heating 
element on the sealing of the scaffold, a slider mechanism was designed and implemented in testing.  A 
retractable metal slider was mounted on a fixed platform with scale marking in millimeters.  To this 
slider, a modular chuck was mounted that clamped the scaffold into place. The chuck was moved 
incrementally to determine the proper distance for heating the scaffold edges while minimizing cell death. 
Time intervals of 1, 2, 3, 4, and 5 seconds were also measured at each distance increment to optimize time 
at a given distance.  As shown in Figure 5.25 below, the modular chuck has three open sides to expose the 
open edges of the scaffold for heat sealing. 
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Figure 5.25: Modular chuck for clamping the scaffold 
5.6 Fabrication of Sealed Scaffold  
 
To produce a sealed scaffold for cell implantation, the electrospun scaffold was folded and heat 
sealed using the final iteration of the heating device. Using the components of this device as shown in 
Figure 5.26 below, the folded scaffold was secured in a custom made PDMS clamp attached onto a 
manually controlled slider, which was used to move the secured scaffold towards the heating element. 
The scaffold was briefly touched to a heating element consisting of a copper wire raised to approximately 
155oF. This mechanism allowed for the complete sealing of the edges.  
 
 
Figure 5.26: Sealing the folded scaffold using a heat sealing mechanism consisting of a slider, clamp, heating element and 
a power switch as shown by the red arrows (left, Figure A), Sealed scaffold (right, Figure B) 
To verify that the edges of the scaffold were completely sealed, migration testing was conducted 
using the sealed scaffold seeded with microspheres. 5 µL of 1:1 mixture of microspheres and DI water 
was pipetted onto a section of scaffold, which was then folded and heat sealed after drying. The sealed 
A B 
65 
 
scaffold was placed in a microcentrifuge tube with 500 µL of DI water and agitated for 10 seconds with a 
Daigger Vortex Genie 2 vortexer. The surrounding liquid was then imaged for the presence of 
microspheres. No microshperes were observed in the supernatant as shown in the figure below, indicating 
that the edges of the folded scaffold were completely sealed by heat. 
 
 
Figure 5.27: Positive control with microspheres (left), Negative control with DI water (middle), Sample supernatant 
showing no microspheres (right) 
5.7 Implant Testing 
 To ensure that the device can withstand the forces involved in the heart contractions and implant 
forces, a small piece of scaffold was loaded onto a catheter. Figure 5.28 shows the size of the scaffold 
used for implant testing, and the second figure shows the piece of scaffold loaded onto the catheter.  
 
 
Figure 5.28: Scaffold loaded in catheter 
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Then, the loaded catheter was forced through a rat heart and pulled back out. It was noted that 
there was still a piece of the scaffold on the end of the catheter. The figure below shows the loaded 
catheter going into the rat heart. 
 
 
Figure 5.29: Insertion of catheter needle into rat heart 
It was suspected that the scaffold stuck because it was not properly hydrated. So, the test 
was conducted again with proper hydration and the scaffold was completely off the catheter. 
Figure 5.30 below shows the rat heart with the scaffold held in place after the catheter was 
removed. 
 
 
Figure 5.30: Scaffold embedded in the rat heart 
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This means that the scaffold stayed in the heart when the catheter was removed, and that it is able 
to withstand the shear forced associated with implantation forces.  
Further implant testing was conducted using an explanted pig heart. A piece of a scaffold was 
loaded onto the tip of a 4-stage catheter and inserted into the ventricular wall of an explanted pig heart 
through a makeshift aorta. The needle of the catheter was first pushed through the heart wall and then the 
inner core of the catheter with the loaded scaffold piece was extended out. Finally, both the inner core and 
the needle were retracted and pulled out of the makeshift aorta, leaving behind the scaffold piece in the 
heart wall as seen in the figure A below. The scaffold piece was later retrieved and was visually inspected 
for any tears or failure. After the scaffold was extracted from the heart, it was observed that there were no 
tears or deformations. Though the scaffold piece appeared to fold on itself due to wetting, it did maintain 
its structural integrity during implantation, as seen in figures B & C below. 
 
Figure 5.31: Implanted scaffold in an explanted pig heart (top, Figure A), Scaffold before implantation (left, Figure B), 
Scaffold after implantation (right, Figure C) 
  
A 
B C 
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Chapter 6 Discussion 
 
An effective minimum scaffold surface area to encapsulate the required number of cells was 
determined using the data from previous research. This size took into consideration that all the cells 
encapsulated within the scaffold need not be in direct contact with the native cardiomyocytes, since the 
signal would be passed along the cells. The loading of the scaffold sheet with the current dimensions, 
onto the tip of a catheter was difficult even after wetting of the scaffold material. In the future, the 
calculated dimensions of 40mmx1.5mm could be reduced further as the transfection efficiency of the 
HMSCs is approaching closer to 100%. The resulting smaller size of the scaffold would allow for easier 
loading onto a catheter device and implantation. 
Providing the scaffold with the desired mechanical strength was an important objective to ensure 
that the scaffold can withstand the shear forces during implantation and performs its function effectively 
by keeping the cells encapsulated. The initial use of fibrin threads to coat the mandrel failed to impart 
structural integrity to the electrospun scaffold, since the fibrin threads had greater adherence to the 
mandrel itself and in some cases even caused the scaffold to tear while removal from the mandrel after 
electrospinning. This problem was approached by coating the mandrel with Teflon tape, which did allow 
for comparatively easier removal of the fibrin threads from the mandrel. But, the fibrin threads still did 
not adhere properly to the scaffold upon removal from the mandrel. This was possibly because of the 
fibrin threads being washed off during the bath step in ethanol and water after electrospinning.  
In another aspect, coating the mandrel with Teflon tape proved advantageous, since it resulted in 
a patterened scaffold. This occurred because of the low conductivity of the Teflon tape in comparison to 
the bare steel mandrel. It was known earlier that a thickness of about 10µm is desirable in the scaffold to 
allow for gap junction formation. However, a greater thickness of about 50µm is needed to ensure 
mechanical strength of the scaffold. Thus, it was deduced that combining these two thickness regions in 
the same scaffold would provide the desired characteristics to our scaffold with the thicker regions 
increasing the structural integrity and the thinner regions allowing for gap junction formation between the 
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encapsulated cells and the native cardiomyocytes. Considering the small size of our scaffold, it was 
essential to scale down the pattern on the electrospun scaffold. This was difficult to achieve using the 
Teflon tape because of its low adherence to the mandrel itself. So, another approach was taken to produce 
a more stable intricate pattern on the mandrel. A laser cut adhesive transparency sheet produced an 
intricate pattern, onto which materials like acrylic lacquer or epoxy could be easily sprayed/spread, 
leaving behind a permanent pattern on the mandrel. This pattern was effectively reversed onto the 
electrospun scaffold to produce a patterned scaffold. However, both the materials did have some 
limitations. The acrylic patterned mandrel proved to be the most effective way of fabricating the patterned 
scaffold with the desired structural integrity and thickness. But, repeated fabrication of similar scaffolds 
would be difficult in the future since the patterned acrylic loses integrity on the mandrel. While epoxy 
maintains sufficient integrity on the mandrel, making fabrication repeatable, the difference in thickness 
between regions is greatly reduced due to the higher conductivity of the epoxy. Thus, a less conductive 
polymer that is stable in ethanol may produce a scaffold with better properties and reproducibility.  
A flat electrospun scaffold with 15 minute spin time showed no microsphere migration and had a 
thickness of about 10µm desirable for gap junction formation. The thickness of this flat sheet could 
effectively be increased for mechanical strength by using a higher spin time. But, as mentioned earlier, 
the higher uniform thickness of the scaffold would hamper the gap junction formation. Thus, migration 
testing was performed on the patterned scaffolds to ensure that the thin regions would prevent cells from 
migrating and to determine the appropriate spin time for the formation of patterned scaffolds. It was 
observed that the patterned scaffold spun at 15 and 30 minutes failed to prevent the microspheres from 
migrating through the pores. The thinner regions of the 15 and 30 minute patterned scaffold showed 
microscopic imperfections. The microscopic imperfections observed on the 15 and 30 minute patterned 
scaffolds could be the cause of microspheres migrating through the material. A patterned scaffold 
produced via a 60 minute spin on an epoxy patterned mandrel was able to prevent microsphere migration 
into the subnatant, even though the desired difference in thickness between the square and columnar 
regions of the scaffold was too low for this application. These results of migration testing on the various 
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patterned scaffolds were promising since they indicate that once a suitable material is found to coat the 
mandrel resulting in the desired thick and thin regions, the spin time could be adjusted corresponding to 
the conductivity of that material to ensure no migration through the thinner regions of the patterned 
scaffold.  
Similarly, the results of the migration testing of the heat sealed scaffold could be extended to a 
patterned scaffold. Because the 15 minute flat scaffold showed no microspheres in the surrounding fluid 
once sealed, it confirms the effectiveness of the heat sealing mechanism and it can be inferred that the 
heat sealed patterned scaffold will yield similar results. Nonetheless, the heat sealing device still has a lot 
of room for improvement, especially in terms of better control of the temperature to which the heating 
element is raised. This could be worked upon with the currently devised heat sealing system, by trying 
different materials for the heating element itself.  
After observing no tears or deformations present on the scaffold when it was removed from the 
heart, it is anticipated that the scaffold can withstand the forces active during implantation. But, since this 
implant testing was done on an explanted rat and pig heart, it does not indicate whether the scaffold 
would have sufficient mechanical strength to withstand normal cardiac forces. This could be easily tested 
by extending this study to implant a piece of scaffold in vivo in a beating rat heart. 
Economics 
  The design of current electronic pacemakers results in revision surgeries approximately every ten 
years. Each reoperation requires more materials to produce replacement battery packs, leads, and 
controllers. Compounded with the cost of each surgical procedure, electronic pacemakers can be 
extremely costly over a lifetime. This device uses a small amount of material for the scaffold, and it can 
remain in the body indefinitely. Thus, biological pacemakers are incredibly cost-effective when compared 
to electronic pacemakers.   
Environmental Impact 
 As previously stated, current electronic pacemakers require revision surgeries approximately 
every ten years. This means that more materials are needed to produce the replacement parts. This device 
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uses a small amount of material used as a scaffold to hold the cells in place, and the device only needs an 
initial implantation surgery. This consumes less material and is more environmentally friendly than 
current electronic pacemakers.   
Societal Influence 
 Improve over the limitations of current metal pacemakers which include electromagnetic 
interference, limited battery life, lead failure, lack of responsiveness to physical and emotional stress, and 
the pacemaker cannot grow with pediatric patients. Since the device has no metal components, there will 
be no electromagnetic interference, no batteries are required, and no leads are used to conduct electrical 
current. The device will use the body’s own pacing mechanism so the device will be able to match the 
heart’s pacing under the stresses accompanied with physical and emotional variances. If the situation is 
such that a pediatric patient needs this device, then it will be able to continually pace the heart will 
sufficient impulse for the rest of the child’s life.  
 Political Ramifications 
 In terms of the global market, this device will greatly shift the market for pacemakers. It is 
assumed that the market will prefer this device over current metallic models because of its natural 
properties. Hopefully, by shifting the market in favor of this device, the quality of life for the patients will 
improve by eliminating the limitations associated with electronic pacemakers.  
Ethical Concern 
 This device is based upon usage of modified stem cells, which are surrounded by ethical concerns 
due to exploratory use of embryonic stem cells. However, because human mesenchymal stem cells can be 
harvested from the bone marrow of living adults, there are few ethical issues with their use beyond 
informed consent of the patient and cell line donor. These issues warrant consideration with normal 
surgical procedures as well.   
Health and Safety Issues 
 As stated earlier, this device is a great improvement on current metallic pacemakers. Still, there is 
an issue with containing the cells inside the implanted scaffold. If the pore size of the scaffold is too large 
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or the edges are not completely sealed, then it is possible that the cells will migrate away from the 
implantation site. Upon migrating, the cells can settle in other places and cause tumors to form. While 
containing the cells was a large portion of this project, the procedure for fabricating the scaffold and 
sealing the edges after seeding the cells is not absolute. As with all surgical procedures, there is the risk of 
human error. These errors could cause defects in the scaffold which could lead to the cells migrating away 
from the implant site and decrease the pacing efficiency.  
Manufacturability 
 Manufacturing the patterned scaffold would not be difficult once a patterned mandrel with an 
ideal material used for coating is made. It can be reused extensively without harming the intricate pattern 
on the mandrel. This makes removal of the scaffold, after electrospinning on top of the mandrel, very easy 
as well. The most difficult part of the fabrication would be sealing the device. To ensure a complete seal 
with full functionality, one must take into account the total shrinkage of the scaffold, cell death upon 
sealing, and uniform sealing around the scaffold with no imperfections that would allow for the seeded 
cells to migrate.  
Sustainability 
 The materials used to fabricate this device are readily available and the final product uses a small 
amount of each. Because only a small amount is used, the risk of depleting these resources through 
manufacturing this device is almost negligible.  
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Chapter 7 Final Design and Validation 
 
Due to the inherent limitations of electronic pacemakers, the clinical need for an effective and 
reliable replacement is significant.  With its success in the pacing of canine models, HCN-transfected 
hMSCs have shown a promising potential in replacing electronic pacemakers.  The implantable biological 
pacemaker design proposed by the project provides a clinically feasible device that can maintain pacing 
function of the transfected hMSCs by preventing cell migration, in addition to being manufacturable and 
implantable.   
Previous projects have demonstrated that the electrospun scaffold used to fabricate the biological 
pacemaker is capable of providing sufficient cell viability.  In addition, the electrospun material has 
suitable physical properties to be manipulated into various shapes and designs tailored to specific 
applications.  However, the designed proposed previously were not clinically viable due to difficulties in 
manufacturing and implantation.  The use of fibrin glue to seal the edges of the device is difficult to 
perform accurately and repetitively.  To achieve sufficient mechanical support, the electrospun scaffold 
used was too thick to allow for the formation of gap junctions. 
After developing our client statement and going through the design process, the project has four 
primary objectives.  First, the minimal scaffold surface area needs to be determined to allow the 
biological pacemaker to be as small as possible in size for easy implantation.  Second, the electrospun 
scaffold needs to prevent cell migration to maintain the pacing function of the HCN-transfected hMSCs.  
Third, the electrospun scaffold needs to provide sufficient mechanical support, so the device can 
withstand the forces during implantation.  Last, by fulfilling all the previous objectives, a clinically 
feasible biological pacemaker design that can be delivered through a minimally invasive procedure was 
developed. 
To determine the minimal surface area of the biological pacemaker, the minimal number of HCN-
transfected hMSCs required to provide sufficient pacing of a human heart should be assessed.  Based on 
the numbers obtained from literature review, it was determined that 150,000 cells are needed to provide 
74 
 
adequate pacing.  With the cell seeding density determined by previous research [] on electrospun 
scaffold, it was calculated that the biological pacemaker needs a minimal surface area of 1.2 cm2, which 
translates to a dimension of 40 mm by 1.5 mm for ease of delivery. 
To demonstrate electrospun scaffold’s ability to prevent cell migration and to determine the 
minimal spin time for preventing migration, migration testing was conducted on flat sheets of electrospun 
scaffolds spun at different times.  When 5 µm microspheres were pipetted onto one side of the scaffold, it 
was found that a flat sheet spun at 15 minutes was able to successfully prevent migration while 
maintaining a thickness of merely approximately 10 µm. 
To allow for gap junction formation, an ideal electrospun scaffold would prevent cell migration 
while having a low thickness.  However, the reduction in thickness significantly weakens the mechanical 
properties of the scaffold.  To ensure that the biological pacemaker has sufficient mechanical strength to 
withstand the stress and strain during implantation, designs of patterned scaffold were proposed to create 
scaffolds with thin sections for gap junction formation and a thick mesh for mechanical support.  
Different materials were used to coat the stainless steel mandrel to create an inverted pattern.  The 
different patterned coatings would change the surface conductivity of the metal mandrel, resulting in a 
difference in the thickness of the deposition of the electrospun polymer.  Each material has its unique 
advantages and disadvantages.  The acrylic lacquer coating had low conductivity, and was able to create 
an intricate patterned scaffold with distinctive thick and thin sections.  However, the acrylic lacquer is not 
chemically stable and adhered to the scaffold upon removal.  On the other hand, the epoxy coating stayed 
adhered to the mandrel.  However, epoxy is highly conductive, resulting in less distinctive thick and thin 
sections.  Ideally, a material combining the low conductivity of acrylic lacquer and chemically stable 
property of epoxy should be used to coat the mandrel. 
Since no feasible sealing methods were proposed previously, a new sealing method was created 
using the thermal properties of the electrospun scaffold.  To ensure ease of repetitive fabrication, a custom 
heat sealing setup was used, which consisted of a heating element, a PDMS clamp holding the scaffold, 
and a controlled slider securing the clamp.  Scaled models of the biological pacemaker were made by 
75 
 
using microspheres.  The sealed pouches showed no leakage of the 5 µm microspheres, demonstrating the 
effectiveness of heating sealing. 
 To demonstrate that the electrospun scaffold can withstand the forces during implantation via a 
catheterization device, a piece of the scaffold with a size of 12 mm x 1 mm was implanted into the left 
ventricular wall of a porcine heart through the aorta.  The scaffold was able to be successfully implanted 
into the tissue while maintaining its structural integrity. 
 
Figure 7.1: Progression of fabrication and implantation of biological pacemaker. 
By fulfilling the previous objectives, the team developed a clinically feasible biological 
pacemaker that can be delivered to the heart using a minimally invasive procedure.  As illustrated in 
Figure 7.1, the fabrication of the device starts with laser cutting of the pattern on an adhesive 
polyethylene terephthalate sheet.  The sheet is then adhered to the stainless steel mandrel to create an 
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inverted coating.  When the PU/PET polymer is spun onto the patterned mandrel, a patterned scaffold 
with thick and thin sections could be obtained.  HCN-transfected hMSCs could then be seeded on one 
side of the electrospun scaffold.  After sufficient cell attachment, the scaffold would then be folded and 
heat sealed to create a pouch.  The pouch fabricated from patterned electrospun scaffold and seeded with 
the cell could finally be implanted into the heart using a custom catheterization device with an inner 
diameter that is greater than the width of the biological pacemaker. 
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Chapter 8 Conclusions and Future Recommendations  
 
Migration testing on flat PU/PET blended electrospun sheets revealed that thicknesses of 10 µm 
could be achieved while effectively preventing migration. Testing on novel patterned scaffolds 
demonstrated that thick and thin regions could be established in micropatterns which would provide 
strength for implantation and allow for gap junction formation between transfected hMSCs and native 
cardiomyocytes. Models of the final sandwich design were successfully sealed via heat shrinking and 
retained the microspheres that were sealed inside them when vortexed aggressively in diH2O. Sample 
scaffolds were also successfully loaded into a catheter and implanted into the left ventricular wall of an 
explanted pig heart without losing structural integrity.  
Because a suitable polymer for patterning the mandrel before electrospinning was not determined, 
the first step in continuing research is to find a polymer that is highly insulating, can be spread over the 
patterned, laser cut stencil, and will adhere to the steel mandrel without solubilizing in water or ethanol 
during sonication. Once a polymer is determined, an ideal spin time can be determined such that the 
sheets are <10 µm in the thin regions and >50 µm in the thick regions. Once a proper polymer sheet is 
developed, cell viability and migration prevention should be reconfirmed. After this is completed, the 
next recommended step is to confirm gap junction formation using a dye transfer assay. This step will 
confirm functionality of the device and is essential to moving the device toward clinical application. The 
final steps necessary to translate this device to the clinic are delivery of models fully loaded with quantum 
dot loaded cells to explanted hearts via catheter to verify efficacy of the device, and pacing trials in an 
animal model. It is believed that completion of these future recommendations is necessary to translate this 
device to clinical applications. In lieu of finding a polymer with the properties described above for 
coating the mandrel, the research group recommends investigating microfabrication of PDMS membranes 
using photolithography. This technique would allow for even nanoscale patterns on PDMS membranes of 
varied thickness. 
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Appendix A: Viability Testing 
 
 In order to determine and demonstrate hMSC viability and attachment on the electrospun 
scaffold, in vitro testing was conducted using a live/dead assay. This assay clearly quantifies the viability 
of the cells on the scaffold in comparison to the controls on tissue culture polystyrene (TCP).  
Thawing and Culturing of Human Mesenchymal Stem Cells 
 To conduct further in vitro experiments evaluating the material properties of the electrospun 
scaffold, human Mesenchymal Stem Cells (hMSCs) were thawed and cultured. The instructions used to 
thaw and culture the cells were provided by Jacques Guyette, a PhD alumni, and Mark Kowaleski and 
Chirantan Kanani, current graduate students in the Biomedical Engineering Department at Worcester 
Polytechnic Institute. 
 Human Mesenchymal Stem Cells were used for the in vitro testing because this specific cell type 
bears the most resemblance with the genetically engineered pacemaker cells, which are hMSCs 
transfected with HCN genes.  Prior to thawing, growth media was prepared in the laminar flow hood by 
adding 50 mL of fetal bovine serum (FBS) and 5 mL of PenStrep to a bottle of 500 mL DMEM to create 
a 10% FBS and 1% PenStrep solution.  Because the hMSCs were intended to be harvested within a week 
for live/dead assay and we are not performing any cell treatment, higher passage cells were sufficient for 
our purpose as long as they still proliferate at a reasonable rate.  As preparation for thawing, 5 mL of 
warmed growth media was added to a 15 mL conical tube and the appropriate vial containing the frozen 
cells were chosen from a cell inventory sheet.  Adequate personal protective equipment was worn when 
taking the interested vial from the cryotank.  As soon as the vial was removed from the cryotank and was 
slightly warmed to avoid bursting of the frozen vial, the vial was half way immersed in 37 °C water bath 
till the content of the vial was completely thawed.  Since the cryoprotectant containing dimethyl sulfoxide 
(DMSO) is toxic to cells in liquid form, the cells in cryoprotectant were immediately transferred drop-
wise to the 15 mL conical tube containing the growth media.  Standard protocol for cell passaging was 
followed from here.  The cell suspension was spun down at 1,000 rpm for 5 minutes in a centrifuge, and 
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the resulting cell pellet was resuspended in 1 mL of the growth media.  Cell counts were achieved by 
taking 10 μL of the cell suspension and adding it to a small vial containing 10 μL of even mixture of 
phosphate buffered saline (PBS) and trypan blue dye.  After proper mixing of the cell suspension with the 
dye solution, 10 μL of the mixture was injected into a hemocytometer and counted using an inverted 
microscope.  After calculating the total cell number, the hMSCs were plated in T-75 culture flasks at a 
seeding concentration of 500,000 cells per flask.  For optimal cell proliferation, each T-75 flask was filled 
with 9 mL of the growth media.  The media was exchanged the day after thawing, and every other day 
afterwards.   
 The hMSCs were cultured in the T-75 flask for a week till complete confluence.  The cells were 
then harvested using the established protocol.  Since FBS in the growth media deactivates trypsin, the 
media in the flask was aspirated and replaced with 9 mL of PBS to rinse off any remaining FBS.  To 
break down the extracellular matrix that adheres the cells to the surface of the flask, 6 mL of trypin, a 
serine protease that cleaves peptide bonds within the extracellular matrix, was added after the PBS was 
aspirated.  As an enzyme, trypsin exhibits greatest activity at the physiological temperature of 37 °C.  To 
accelerate the breakdown of the extracellular matrix and to reduce damage to the cells, the flask was 
placed back into the incubator for 5 minutes.  After taken out of the incubator, the flask was checked 
under the inverted microscope for cell attachment.  When no cells were visibly attached to the bottom of 
the flask when agitated, the trypsin solution containing the cells was transferred to a 15 ml conical tube 
with 5 mL of growth media.  Additional 4 mL of media was used to rinse the T-75 flask to remove any 
lingering on the plastic surface and again transferred to the conical tube.  The content of the conical tube 
was carefully mixed to ensure full deactivation of the trypsin.  Similar to the thawing procedure, the cell 
suspension was then spun down at 1,000 rpm for 5 minutes, resuspended in 1 mL of media, and counted 
using the hemocytometer.  After calculating the total cell number, the hMSCs were seeded in different 
containers appropriate for corresponding in vitro experiments. 
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Live/Dead Assay 
Biosurfaces, Inc. was responsible for making the electrospun scaffold used in viability testing.  
The protocol for the test was developed by Nancy Duffy, a past graduate student in the WPI Myocardial 
Regeneration lab.  The purpose of the test is to determine and demonstrate hMSC viability and attachment 
on the electrospun scaffold.  As preparation for cell seeding, the scaffold was cut into 6 mm by 6 mm 
squares and place in a 98 well plate to be sterilized by Ethylene Oxide (EtO) gas as shown in the figure 
below. 
 
96 well plate containing 4 6 mm by 6 mm sheets of the electrospun scaffold after EtO gas sterilization. 
 Following the established protocol, 100 mL of cell suspension containing 200,000 hMSCs were 
added to each well with the scaffold.  To ensure optimal attachment of the cells on the scaffold, the wells 
were checked to ensure that no scaffold was floating on top of the cell suspension.  In addition, 100 mL of 
cell suspension with 50,000 hMSCs were added to two empty wells for controls. The growth media was 
changed the day after seeding and every other day afterwards. 
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After seven days, the cells were stained with live/dead staining to determine their viability on the 
electrospun scaffold.  The proper concentrations of Ethidium Bromide and the fluorescent dye calcein 
were provided by Chirantan Kanani.  The mixture solution of the two dyes was prepared by adding 2 µL 
of Ethidium Bromide and 0.5 µL of calcein in 1 mL of sterile serum-free DMEM.  Then, the wells 
containing the cells were washed with PBS while ethanol was added to one of the plastic wells to create a 
negative control.  After each well was aspirated, the live/dead solution was added and incubated for 15 
minutes at 37 °C.  The plate was imaged immediately afterwards and the resulting images can be seen 
below. 
 
 
Positive (left) and negative (right) controls of the live/dead stain on hMSCs after 7 days of culturing. 
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Live/dead stain of hMSCs on electrospun scaffold at day 7. 
 As shown in figure 5.13, the experiment demonstrated the effectiveness of the staining in 
identifying non-viable cells.  The negative control treated with ethanol showed only red signal, which is 
an indication of non-viable cells. In comparison, a green signal was detected in the positive control and 
the experimental sample indicating the presence of viable cells.  However, the prevalence of non-viable 
cells in the positive control raised some serious concerns.  It was proposed that future viability testing 
would be performed on cells cultured for 24 hours after seeding. Additionally, cell morphology will be 
examined while the cells are attached to the scaffold in order to determine the effects that the material has 
on the cells.  
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